Concepedia

Author

Ted Drogendijk

Astellas Pharma (Netherlands)

Also Known As

P. L. I. Dellemijn, Peter Boerrigter, T Drogendijk, T. Drogendijk, T. E. Drogendijk, T.E. DROGENDIJK, T.E. Drogendijk, Ted Drogendijk

31

Publications

2.1K

Citations

13

H-Index

18

Concepts

All Affiliations

Astellas Pharma (Netherlands)Royal Hallamshire HospitalAstellas Pharma (United Kingdom)Rotterdam University of Applied SciencesSorbonne Université
TD

About

Ted Drogendijk is an author at Astellas Pharma (Netherlands) specializing in medicine, urology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

1.4K

2

Pharmacology

7

7

1.3K

3

Health Sciences

1

1

29

4

Immunology

1

1

29

5

Hematology

1

1

29

Ted Drogendijk

×

13

Publications

1.9K

Citations

11

H-Index

YearCitations

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Vik Khullar, G. Amarenco, J.C. Angulo,

European Urology

2012

416

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson,

European Urology

2012

350

RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER

L. Cardozo, M. LISEC, R. J. Millard,

The Journal of Urology

2004

335

A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial

Christopher R. Chapple, R. Martínez-García, Luigi Selvaggi,

European Urology

2005

330

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial

Linda Cardozo, Elke Heßdörfer, Rodolfo Milani,

British Journal of Urology

2008

132

Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial

Philip Van Kerrebroeck, Christopher R. Chapple, Ted Drogendijk,

European Urology

2013

102

Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension

Marcus J. Drake, Christopher R. Chapple, Roman Sokol,

European Urology

2014

75

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder

Charlotte Eltink, Jennifer Lee, Marloes Schaddelee,

International Journal of Clinical Pharmacology and Therapeutics

2012

54

Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin ( <scp>SUNRISE</scp> )

Linda Cardozo, G. Amarenco, Jura Mikulas,

British Journal of Urology

2013

35

The effects of an ACTH (4?9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial

Joop van Gerven, A. Hovestadt, J. Moll,

Journal of Neurology

1994

35

Page 1